Get notified when SRRK files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Loss On Extinguishment Of Debt (new) — Company recognized $3.3M loss when terminating Oxford loan and refinancing with Blue Owl in February 2026.
Scholar Rock narrows net loss 0.1% to -$109.9M in Q2 2026; BLA resubmitted with Sept PDUFA date
Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 6, 2025 · ~2 min read
Key Changes
-
high
BLA resubmitted in March 2026 after Sept 2025 CRL for third-party fill-finish facility issues; new PDUFA date Sept 30, 2026, delaying approval ~1 year. CRL did not cite efficacy or safety concerns.
MD&A: BLA resubmission verify on EDGAR → -
high
Raised $160.8M via ATM equity offering (3.5M shares) in H1 2026, plus $200M debt from Blue Owl facility (up to $350M capacity); cash and marketable securities rose 67% YoY to $492.1M.
Notes: Financing activity view on EDGAR → -
high
Initiated Phase 2 FORGE trial in FSHD (Q2 2026) and Phase 2 OPAL trial in SMA patients under 2 years (Q3 2025), expanding apitegromab development beyond core SMA indication.
MD&A: Clinical pipeline verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (WOLF 10-K) is open in full — no account needed.
Partner
Trade SRRK commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 27, 2026 · How we verify